Skip to main content
. 2021 Sep 28;19(8):1211–1223. doi: 10.20892/j.issn.2095-3941.2020.0294

Figure 5.

Figure 5

The PYK2 inhibitor, PF562711, abrogates vemurafenib-induced invadopodia formation and cell invasion. (A–C) Western blot analysis of p-PYK2 levels (A), representative images of fluorescence staining of actin (B), and quantification of invadopodia (C) in WM793 cells treated with dimethyl sulfoxide or PF562711 (n = 3). (D) Quantification of invadopodia in WM793 cells treated with and without vemurafenib and/or PF562711 (n = 3). (E, F) Quantification of invadopodia (E) and invaded cells (F) in vemurafenib resistant WM793 cells treated with and without vemurafenib and/or PF562711 (n = 3). Scale bars = 10 μm. **P < 0.01; ***P < 0.001.